

### This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Assays &amp; screens</b>			
Single-cell PCR analysis of tumor samples to identify prognostic gene expression signatures	<p>A method to measure gene expression in individual tumor cells could help identify new cancer biomarkers and targets. Xenograft mouse tumors generated from a single colon cancer cell were surgically extracted, separated and sorted. Expression of selected genes was then measured by microfluidic single-cell PCR. Identification of genes expressed in specific subsets of tumor cells led to the discovery of a two-gene prognostic signature that could predict disease-free survival for patients with colorectal cancer. Next steps could include application of this methodology to clinical tumor samples.</p> <p>Stephen Quake and Michael Clarke, co-senior authors of the publication, are founders of QuanticeL Pharmaceuticals Inc., which uses single-cell genomic analysis of patient tumor samples to identify predictive biomarkers. The company declined to comment on the licensing status of this work.</p> <p><b>SciBX 4(46); doi:10.1038/scibx.2011.1305</b> Published online Dec. 1, 2011</p>	Patent application filed; licensing status unavailable	<p>Dalerba, P. <i>et al. Nat. Biotechnol.</i>; published online Nov. 13, 2011; doi:10.1038/nbt.2038</p> <p><b>Contact:</b> Stephen R. Quake, Stanford University, Stanford, Calif. e-mail: <a href="mailto:quake@stanford.edu">quake@stanford.edu</a></p> <p><b>Contact:</b> Michael F. Clarke, same affiliation as above e-mail: <a href="mailto:mfclarke@stanford.edu">mfclarke@stanford.edu</a></p>